Literature DB >> 25006399

Transient but not genetic loss of miR-451 is protective in the development of pulmonary arterial hypertension.

Jennifer S Grant1, Ian Morecroft1, Yvonne Dempsie1, Eva van Rooij2, Margaret R MacLean1, Andrew H Baker1.   

Abstract

MicroRNAs are small noncoding RNAs involved in the regulation of gene expression and have recently been implicated in the development of pulmonary arterial hypertension (PAH). Previous work has established that miR-451 is upregulated in rodent models of PAH. The role of miR-451 in the pulmonary circulation is unknown. We therefore sought to assess the involvement of miR-451 in the development of PAH. Silencing of miR-451 was performed in vivo using miR-451 knockout mice and an anti-miR targeting mature miR-451 in rats. Coupled with exposure to hypoxia, indices of PAH were assessed. The effect of modulating miR-451 on human pulmonary artery smooth muscle cell proliferation and migration was analyzed. We observed a reduction in systolic right ventricular pressure in hypoxic rats pretreated with anti-miR-451 compared with hypoxia alone ([Formula: see text] mmHg and [Formula: see text] mmHg, respectively; [Formula: see text]). In miR-451 knockout mice, compared with wild-type hypoxic mice, no significant differences were observed following exposure to chronic hypoxia. In vitro analysis demonstrated that overexpression of miR-451 in human pulmonary artery smooth muscle cells promoted migration under serum-free conditions. No effect on cellular proliferation was observed. In conclusion, transient inhibition of miR-451 attenuated the development of PAH in hypoxia-exposed rats. Genetic deletion of miR-451 had no beneficial effect on indices of PAH, potentially because of pathway redundancy compensating for the loss of miR-451.

Entities:  

Keywords:  hypoxia; microRNA; migration; pulmonary vascular disorder; smooth muscle cell

Year:  2013        PMID: 25006399      PMCID: PMC4070830          DOI: 10.1086/674751

Source DB:  PubMed          Journal:  Pulm Circ        ISSN: 2045-8932            Impact factor:   3.017


  43 in total

1.  Specificity of microRNA target selection in translational repression.

Authors:  John G Doench; Phillip A Sharp
Journal:  Genes Dev       Date:  2004-03-10       Impact factor: 11.361

2.  Primary pulmonary hypertension. I. Clinical and hemodynamic study.

Authors:  D T DRESDALE; M SCHULTZ; R J MICHTOM
Journal:  Am J Med       Date:  1951-12       Impact factor: 4.965

3.  Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension.

Authors:  L Taraseviciene-Stewart; Y Kasahara; L Alger; P Hirth; G Mc Mahon ; J Waltenberger; N F Voelkel; R M Tuder
Journal:  FASEB J       Date:  2001-02       Impact factor: 5.191

4.  The serotonin transporter, gender, and 17β oestradiol in the development of pulmonary arterial hypertension.

Authors:  Kevin White; Yvonne Dempsie; Margaret Nilsen; Audrey F Wright; Lynn Loughlin; Margaret R MacLean
Journal:  Cardiovasc Res       Date:  2010-12-22       Impact factor: 10.787

5.  Molecular signature of a right heart failure program in chronic severe pulmonary hypertension.

Authors:  Jennifer I Drake; Herman J Bogaard; Shiro Mizuno; Berrick Clifton; Bin Xie; Yuan Gao; Catherine I Dumur; Paul Fawcett; Norbert F Voelkel; Ramesh Natarajan
Journal:  Am J Respir Cell Mol Biol       Date:  2011-06-30       Impact factor: 6.914

6.  Conserved vertebrate mir-451 provides a platform for Dicer-independent, Ago2-mediated microRNA biogenesis.

Authors:  Jr-Shiuan Yang; Thomas Maurin; Nicolas Robine; Kasper D Rasmussen; Kate L Jeffrey; Rohit Chandwani; Eirini P Papapetrou; Michel Sadelain; Dónal O'Carroll; Eric C Lai
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-10       Impact factor: 11.205

Review 7.  Cellular and molecular pathobiology of pulmonary arterial hypertension.

Authors:  Marc Humbert; Nicholas W Morrell; Stephen L Archer; Kurt R Stenmark; Margaret R MacLean; Irene M Lang; Brian W Christman; E Kenneth Weir; Oliver Eickelberg; Norbert F Voelkel; Marlene Rabinovitch
Journal:  J Am Coll Cardiol       Date:  2004-06-16       Impact factor: 24.094

8.  MicroRNA expression dynamics during murine and human erythroid differentiation.

Authors:  Mei Zhan; Chris P Miller; Thalia Papayannopoulou; George Stamatoyannopoulos; Chao-Zhong Song
Journal:  Exp Hematol       Date:  2007-07       Impact factor: 3.084

9.  Serotonin transporter, sex, and hypoxia: microarray analysis in the pulmonary arteries of mice identifies genes with relevance to human PAH.

Authors:  Kevin White; Lynn Loughlin; Zakia Maqbool; Margaret Nilsen; John McClure; Yvonne Dempsie; Andrew H Baker; Margaret R MacLean
Journal:  Physiol Genomics       Date:  2011-02-08       Impact factor: 3.107

10.  miRBase: microRNA sequences, targets and gene nomenclature.

Authors:  Sam Griffiths-Jones; Russell J Grocock; Stijn van Dongen; Alex Bateman; Anton J Enright
Journal:  Nucleic Acids Res       Date:  2006-01-01       Impact factor: 16.971

View more
  9 in total

1.  Plasma miR-451 with echocardiography serves as a diagnostic reference for pulmonary hypertension.

Authors:  Xiao-Wei Song; Lu-Lu Zou; Ling Cui; Song-Hua Li; Yong-Wen Qin; Xian-Xian Zhao; Qing Jing
Journal:  Acta Pharmacol Sin       Date:  2018-05-24       Impact factor: 6.150

Review 2.  Toward the promise of microRNAs - Enhancing reproducibility and rigor in microRNA research.

Authors:  Kenneth W Witwer; Marc K Halushka
Journal:  RNA Biol       Date:  2016-09-19       Impact factor: 4.652

3.  Serum miR-204 and miR-451 Expression and Diagnostic Value in Patients with Pulmonary Artery Hypertension Triggered by Congenital Heart Disease.

Authors:  Dejiang Ji; Yan Qiao; Xiaoping Guan; Tao Zhang
Journal:  Comput Math Methods Med       Date:  2022-06-13       Impact factor: 2.809

Review 4.  Discerning functional hierarchies of microRNAs in pulmonary hypertension.

Authors:  Vinny Negi; Stephen Y Chan
Journal:  JCI Insight       Date:  2017-03-09

Review 5.  Epigenetic modulation as a therapeutic approach for pulmonary arterial hypertension.

Authors:  Jun-Dae Kim; Aram Lee; Jihea Choi; Youngsook Park; Hyesoo Kang; Woochul Chang; Myeong-Sok Lee; Jongmin Kim
Journal:  Exp Mol Med       Date:  2015-07-31       Impact factor: 8.718

6.  An improved method for detecting circulating microRNAs with S-Poly(T) Plus real-time PCR.

Authors:  Yanqin Niu; Limin Zhang; Huiling Qiu; Yike Wu; Zhiwei Wang; Yujia Zai; Lin Liu; Junle Qu; Kang Kang; Deming Gou
Journal:  Sci Rep       Date:  2015-10-13       Impact factor: 4.379

Review 7.  Epigenetic Regulation and Its Therapeutic Potential in Pulmonary Hypertension.

Authors:  Yu Wang; Lingling Yan; Ziming Zhang; Eric Prado; Linchen Fu; Xuefeng Xu; Lizhong Du
Journal:  Front Pharmacol       Date:  2018-03-20       Impact factor: 5.810

Review 8.  Elucidating the contributory role of microRNA to cardiovascular diseases (a review).

Authors:  Jason L Johnson
Journal:  Vascul Pharmacol       Date:  2018-10-31       Impact factor: 5.773

9.  Circulating whole genome miRNA expression corresponds to progressive right ventricle enlargement and systolic dysfunction in adults with tetralogy of Fallot.

Authors:  Chad S Weldy; Saad Ali Syed; Myriam Amsallem; Dong-Qing Hu; Xuhuai Ji; Rajesh Punn; Anne Taylor; Brittany Navarre; Sushma Reddy
Journal:  PLoS One       Date:  2020-11-11       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.